10 news items
Bristol Myers Squibb Provides Update on Phase 3 CheckMate -73L Trial
BMY
10 May 24
and YERVOY can cause immune-mediated pneumonitis. The incidence of pneumonitis is higher in patients who have received prior thoracic radiation
CHMP Adopts Positive Opinion Recommending Approval of Bristol Myers Squibb's Opdivo® (nivolumab) in Combination with Cisplatin and Gemcitabine for the First-Line Treatment of Adult Patients with Unresectable or Metastatic Urothelial Carcinoma
BMY
26 Apr 24
OPDIVO and YERVOY can cause immune-mediated pneumonitis. The incidence of pneumonitis is higher in patients who have received prior thoracic
U.S. FDA Approves Bristol Myers Squibb and 2seventy bio's Abecma for Triple-Class Exposed Relapsed or Refractory Multiple Myeloma After Two Prior Lines of Therapy
BMY
TSVT
5 Apr 24
adverse reactions (incidence greater than or equal to 20%) include pyrexia, CRS, hypogammaglobulinemia, infections – pathogen unspecified
European Commission Expands Approval of Bristol Myers Squibb's Reblozyl® (luspatercept) to Include First-Line Treatment of Transfusion-Dependent Anemia in Adults with Lower-Risk Myelodysplastic Syndromes (LR-MDS)
BMY
2 Apr 24
Hypertension was reported in 11.4% (63/554) of REBLOZYL-treated patients. Across clinical studies, the incidence of Grade 3 to 4
Bristol Myers Squibb to Present Data at the American College of Cardiology Annual Scientific Session 2024 Reinforcing Extensive Body of Evidence in Clinical and Real-World Settings Across Cardiovascular Portfolio
BMY
25 Mar 24
from a 10-month post-launch evaluation of the REMS Program finds 2.8% incidence of LVEF <50% in over 1500 patients, strengthening the safety profile
cda19o7gvp77u77 t4legh9cbyx6em0o99hf0rdp5axcbtqdoqfv7ejr
BMY
14 Mar 24
(incidence ≥ 30%) in:
LBCL are fever, cytokine
yvh4ra7j6ijqja39nqeywhhui9w9jixw9803s7qnsi6xu4g9nn7
BMY
7 Mar 24
-Mediated Pneumonitis
OPDIVO can cause immune-mediated pneumonitis. The incidence of pneumonitis
84rw5n9ct0fla
BMY
23 Feb 24
, the incidence of Grade 3 to 4 hypertension ranged from 2% to 9.6%. In patients with beta thalassemia with normal baseline blood pressure, 13 (6.2
huu kzxii
BMY
BTAI
EXEL
14 Feb 24
of anal cancer and the presence of significant market participants. In The Middle East and Africa, due to the high incidence rate of anal cancer
7h0j54eiog6
BMY
14 Feb 24
to sleep disorders.
The incidences of CNS adverse reactions reported were similar in patients
- Prev
- 1
- Next